<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146341">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01963286</url>
  </required_header>
  <id_info>
    <org_study_id>CR-12-092-GE-HV</org_study_id>
    <nct_id>NCT01963286</nct_id>
  </id_info>
  <brief_title>Reduction of Inappropriate Shocks of Implantable Cardioverter Defibrillators (ICDs) With Enhanced SVT Discriminators</brief_title>
  <acronym>ReduceIT</acronym>
  <official_title>Reduction of Inappropriate Shocks of Implantable Cardioverter Defibrillators (ICDs) With Enhanced SVT Discriminators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical investigation is the continued assessment of the decision
      accuracy of St. Jude Medical (SJM) ICD with enhanced SVT discriminators in the treatment of
      subjects with primary and secondary prevention of sudden cardiac death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With Ellipse™ and Fortify Assura™ ICD family, St. Jude Medical introduced enhanced device
      algorithms that may be helpful to further improve SVT discrimination success: SecureSense™,
      Far field morphology, Chamber Onset. These algorithms in combination with a tailored device
      setting (primary or secondary prevention) will be prospectively investigated within this
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Inappropriate ICD shocks</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Freedom from inappropriate automatically delivered ICD-shocks within 12 months Follow-Up (FU) period after ICD/CRT-D implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICD shocks for any reason</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Freedom from automatically delivered ICD shocks for any reason during FU period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inappropriate ICD therapies</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Freedom from automatically delivered inappropriate ICD therapies during FU period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Untreated VT/VF</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Freedom from untreated sustained ventricular tachycardia (VT) / ventricular fibrillation (VF) during FU period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accuracy of ICD therapy decision</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Accuracy of ICD therapy decision (VT/VF and nonVT/VF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specificity for…
… other than sustained VT/VF
… SVT (Supraventricular tachycardia)
… different subtypes of SVTs (Sinus Tachycardia, Atrial Fibrillation, Atrial Flutter, other SVT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac deaths</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cardiac deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sensitivity for sustained VT/VF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICD/CRT-D related SAE</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>ICD/CRT-D related Serious Adverse Events (SAE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">697</enrollment>
  <condition>Tachycardia</condition>
  <arm_group>
    <arm_group_label>Enhanced SVT discriminators</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with activated enhanced SVT discriminators (in accordance with predefined mandatory study settings)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD with enhanced SVT discriminators</intervention_name>
    <description>ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.</description>
    <arm_group_label>Enhanced SVT discriminators</arm_group_label>
    <other_name>Ellipse (St. Jude Medical)</other_name>
    <other_name>Fortify Assura (St. Jude Medical)</other_name>
    <other_name>Unify Assura (St. Jude Medical)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ischemic or nonischemic cardiomyopathy

          -  Primary prevention or secondary prevention of Sudden cardiac death (SCD)

          -  Indication for ICD/CRT-D new implantation per current guidelines (1, 2, 3-chamber)

          -  The patient is ≥ 18 years of age

          -  The patient is able to understand the patient information and is capable to provide
             informed consent.

          -  The patient has provided written informed consent prior to any investigational
             related procedure

        Exclusion Criteria:

          -  Previously implanted ICD/CRT-D

          -  Hypertrophic (with or without obstructive) cardiomyopathy

          -  Ion channel disorders (Long/Short-QT, Brugada syndrome etc…)

          -  New York Heart Association (NYHA) Class IV

          -  Recent cardiac decompensation (within previous 3 months)

          -  The patient is unable to comply with the follow up schedule.

          -  The patient is participating in another investigational device or drug investigation.

          -  The patient is pregnant or is planning to become pregnant during the duration of the
             investigation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johann C Geller, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Zentralklinik Bad Berka</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johann C Geller, Prof. Dr.</last_name>
    <phone>+49 36458-51201</phone>
    <email>kar@zentralklinik.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Praxis Dr. med. Bernhardt</name>
      <address>
        <city>Annaberg-Buchholz</city>
        <zip>09456</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Bernhardt, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH</name>
      <address>
        <city>Bad Berka</city>
        <zip>99438</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johann C Geller, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hufeland Klinikum GmbH</name>
      <address>
        <city>Bad Langensalza</city>
        <zip>99947</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Oehler, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum am Küchwald GmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilfried Dänschel, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Stellmach</name>
      <address>
        <city>Chemnitz</city>
        <zip>09126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Wöhrle, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Veltmann, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Holzminden gGmbH</name>
      <address>
        <city>Holzminden</city>
        <zip>37603</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine-Susan Schulz, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Sabine-Susan Schulz, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Frau Dr. med. Gärtner</name>
      <address>
        <city>Leisnig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Gärtner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Eckardt, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrecht Esser, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christliches Krankenhaus Quakenbrück gGmbH</name>
      <address>
        <city>Quakenbrück</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Götting, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gem.-Praxis Dres. med. Ebert / Stenzel</name>
      <address>
        <city>Riesa</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans H Ebert, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hegau-Bodensee-Klinikum mbH</name>
      <address>
        <city>Singen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Kollum, PD Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 11, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ICD</keyword>
  <keyword>CRT-D</keyword>
  <keyword>Sudden cardiac death</keyword>
  <keyword>Device settings</keyword>
  <keyword>Optimized programming strategy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
